Condition: Moderate to Severe Atopic Dermatitis · Sponsor: Sitryx Therapeutics Ltd
The purpose of this study is to evaluate the study drug, SYX-5219, in a multi-part First-in-Human (FiH) study to be conducted in healthy volunteers and participants with Atopic Dermatitis (AD). The objectives of this study are to determine the safety, tolerability and levels of SYX-5219 in the blood and urine when SYX-5219 is given in each part of the study (SAD, MAD, Food Effect and Participants with AD). The study will be split into up to 3 parts as follows: * Part 1 - Single Ascending Dose (SAD) and Food Effect in healthy volunteers * Part 2 - Multiple Ascending Dose (MAD) in healthy volunteers * Part 3 - Multiple Dose in Participants with AD - enrolling up to 45 males and females with a confirmed diagnosis of AD of at least 6 months, evaluating multiple dose administrations of SYX-5219 or placebo daily over a period of 42 days.
This description comes directly from the study's public registry record.
Sitryx Therapeutics · +44 (0)1865 648401 · info@sitryx.com
Sitryx Therapeutics · +44 (0) 1865 648401 · info@sitryx.com
Always discuss trial participation with your own doctor first.
| Sitryx Clinical Site | Arkansas City, Arkansas, United States | Recruiting |
| Sitryx Clinical Site | Fremont, California, United States | Recruiting |
| Sitryx Clinical Site | Plainfield, Indiana, United States | Recruiting |
| Sitryx Clinical Site | Boardman, Ohio, United States | Recruiting |
| Sitryx Clinical Site | Philadelphia, Pennsylvania, United States | Recruiting |
| Sitryx Clinical Site | Bountiful, Utah, United States | Recruiting |
| Sitryx Clinical Site | Sofia, Bulgaria | Recruiting |
| Sitryx Clinical Site | Herlev, Herlev, Denmark | Not Yet Recruiting |
| Sitryx Clinical Site | Berlin, Germany | Recruiting |
| Sitryx Clinical Site | Frankfurt, Germany | Recruiting |
| Sitryx Clinical Site | Freiburg im Breisgau, Germany | Active Not Recruiting |
| Sitryx Clinical Site | Dublin, Ireland | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07558668